Evaluating HBVZ10-Based Therapies for cccDNA Clearance: Virological Foundation and Synergistic Combinations

Hbvtech, Germantown MD

Investigators

Abstract

The goal of this SBIR Research Topic is to support small businesses in the development of new drug classes with novel mechanisms of action for HIV, Hepatitis B (HBV), and Tuberculosis (Mtb). HBV and Mtb drugs must be compatible with current antiretroviral therapy regimens. The goal of this contract is to advance development of HBVZ10, a gene therapy candidate using an optimized AAV8 vector to deliver human anti-HBs antibody genes into muscle cells for treatment and potential cure of HBV infection.